Fibroblast-targeted MLN4924 suppresses autoimmune myocarditis by dually modulating IL-17A and TGF-β pathways
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.116206 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Wenwen Shen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, PR China; Institutes of Biology and…. Hauptthemen laut MEDLINE: Autoimmune Diseases, Interleukin-17, Myocarditis, Transforming Growth Factor beta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Shanghai Rising-Star Program, National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.
Abstract (Originalsprache)
BACKGROUND: Myocarditis is a leading cause of heart failure in young individuals and may progress to dilated cardiomyopathy due to inflammation-driven cardiac fibrosis. Cardiac fibroblasts (CFs) are key contributors to this process, mediating both IL-17A-driven inflammatory responses and TGF-β-induced fibrotic remodeling. However, effective therapies that concurrently target these dual pathological pathways in CFs are lacking. METHODS: We evaluated the neddylation inhibitor MLN4924 in a mouse model of experimental autoimmune myocarditis (EAM). A fibroblast-targeted biomimetic nanoparticle (FMlipo@MLN4924) was engineered and its delivery efficiency and therapeutic effects were assessed in vitro and in vivo. RESULTS: Systemic MLN4924 treatment significantly alleviated myocardial inflammation, reduced cardiac fibrosis by approximately 50% and preserved cardiac function in EAM mice. Mechanistically, MLN4924 dually suppressed IL-17A-induced chemokine production and TGF-β-driven fibrotic activation in CFs. The FMlipo@MLN4924 system demonstrated more than a 2.5-fold increase in cardiac accumulation compared to non-targeted liposomes. This targeted delivery resulted in superior therapeutic efficacy, achieving enhanced suppression of immune infiltration and fibrotic remodeling with no observable toxicity. CONCLUSION: MLN4924 exerts dual anti-inflammatory and anti-fibrotic effects in autoimmune myocarditis by regulating IL-17A and TGF-β pathways in CFs. Fibroblast-membrane camouflaging enhances MLN4924 delivery and performance, presenting a promising precision medicine strategy for immune-mediated cardiac injury with clear translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, PR China; Institutes of Biology and Medical Sciences, Soochow University, Building 703, 199 Ren-ai Road,…
- Department of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, PR China.
- Institutes of Biology and Medical Sciences, Soochow University, Building 703, 199 Ren-ai Road, Suzhou 215123, PR China.
- Department of Clinical Laboratory, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, PR China.
- Department of Clinical Laboratory, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, PR China. Electronic address: zongming@tongji.edu.cn.
- Institutes of Biology and Medical Sciences, Soochow University, Building 703, 199 Ren-ai Road, Suzhou 215123, PR China. Electronic address: minl_zju@126.com.
Förderung
- Shanghai Rising-Star Program
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Shen, W., Guo, F., Jiang, H., Gao, J., Chen, W., Yu, Z., Yuan, J., Huang, M., Zong, M., Li, M., & Fan, L. (2026). Fibroblast-targeted MLN4924 suppresses autoimmune myocarditis by dually modulating IL-17A and TGF-β pathways. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116206
Vancouver
Shen W, Guo F, Jiang H, Gao J, Chen W, Yu Z, et al. Fibroblast-targeted MLN4924 suppresses autoimmune myocarditis by dually modulating IL-17A and TGF-β pathways. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116206
BibTeX
@article{Shen2026,
author = {Shen, Wenwen and Guo, Fei and Jiang, Hao and Gao, Jiapeng and Chen, Wenwen and Yu, Zhaoda and Yuan, Jiayi and Huang, Mengyu and Zong, Ming and Li, Min and Fan, Lieying},
title = {Fibroblast-targeted MLN4924 suppresses autoimmune myocarditis by dually modulating IL-17A and TGF-β pathways},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.116206}
}
EUVIMED